Restoring Lives
One Story At A Time

We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced options for patients who may be underserved by existing therapies. More

In the News

March 6, 2019

Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial ResultsRead More

February 21, 2019

Assertio Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results After The Close of Markets on Wednesday, March 6, 2019Read More

February 19, 2019

Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting CosyntropinRead More

More News